Literature DB >> 33801414

CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6.

Andy Chevigné1, Bassam Janji2, Max Meyrath1, Nathan Reynders1,3, Giulia D'Uonnolo1,3, Tomasz Uchański1, Malina Xiao2, Guy Berchem2,4, Markus Ollert1,5, Yong-Jun Kwon6, Muhammad Zaeem Noman2, Martyna Szpakowska1,2.   

Abstract

Atypical chemokine receptors (ACKRs) are important regulators of chemokine functions. Among them, the atypical chemokine receptor ACKR2 (also known as D6) has long been considered as a scavenger of inflammatory chemokines exclusively from the CC family. In this study, by using highly sensitive β-arrestin recruitment assays based on NanoBiT and NanoBRET technologies, we identified the inflammatory CXC chemokine CXCL10 as a new strong agonist ligand for ACKR2. CXCL10 is known to play an important role in the infiltration of immune cells into the tumour bed and was previously reported to bind to CXCR3 only. We demonstrated that ACKR2 is able to internalize and reduce the availability of CXCL10 in the extracellular space. Moreover, we found that, in contrast to CC chemokines, CXCL10 activity towards ACKR2 was drastically reduced by the dipeptidyl peptidase 4 (DPP4 or CD26) N-terminal processing, pointing to a different receptor binding pocket occupancy by CC and CXC chemokines. Overall, our study sheds new light on the complexity of the chemokine network and the potential role of CXCL10 regulation by ACKR2 in many physiological and pathological processes, including tumour immunology. Our data also testify that systematic reassessment of chemokine-receptor pairing is critically needed as important interactions may remain unexplored.

Entities:  

Keywords:  ACKR2; ACKR3; CD26; CXCL10; CXCL12; CXCL2; CXCR3; D6; DPP4; IP-10; NanoBRET; NanoBiT; scavenger

Year:  2021        PMID: 33801414      PMCID: PMC7958614          DOI: 10.3390/cancers13051054

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  70 in total

Review 1.  Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines.

Authors:  Massimo Locati; Yeny Martinez de la Torre; Emanuela Galliera; Raffaella Bonecchi; Haribabu Bodduluri; Gianluca Vago; Annunciata Vecchi; Alberto Mantovani
Journal:  Cytokine Growth Factor Rev       Date:  2005-07-05       Impact factor: 7.638

2.  Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.

Authors:  Andy Chevigné; Virginie Fievez; Martyna Szpakowska; Aurélie Fischer; Manuel Counson; Jean-Marc Plesséria; Jean-Claude Schmit; Sabrina Deroo
Journal:  Biochim Biophys Acta       Date:  2014-01-27

3.  Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.

Authors:  P Proost; E Schutyser; P Menten; S Struyf; A Wuyts; G Opdenakker; M Detheux; M Parmentier; C Durinx; A M Lambeir; J Neyts; S Liekens; P C Maudgal; A Billiau; J Van Damme
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

4.  The atypical chemokine receptor D6 controls macrophage efferocytosis and cytokine secretion during the resolution of inflammation.

Authors:  Ester Pashover-Schallinger; Miran Aswad; Sagie Schif-Zuck; Haim Shapiro; Pierre Singer; Amiram Ariel
Journal:  FASEB J       Date:  2012-05-31       Impact factor: 5.191

5.  ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin.

Authors:  Friederike Saaber; Dagmar Schütz; Elke Miess; Philipp Abe; Srinidhi Desikan; Praveen Ashok Kumar; Sara Balk; Ke Huang; Jean Martin Beaulieu; Stefan Schulz; Ralf Stumm
Journal:  Cell Rep       Date:  2019-02-05       Impact factor: 9.423

6.  Atypical chemokine receptor ACKR2 mediates chemokine scavenging by primary human trophoblasts and can regulate fetal growth, placental structure, and neonatal mortality in mice.

Authors:  Pek Joo Teoh; Fiona M Menzies; Chris A H Hansell; Mairi Clarke; Carolann Waddell; Graham J Burton; Scott M Nelson; Robert J B Nibbs
Journal:  J Immunol       Date:  2014-10-08       Impact factor: 5.422

7.  Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration.

Authors:  Timothy J Zumwalt; Mildred Arnold; Ajay Goel; C Richard Boland
Journal:  Oncotarget       Date:  2015-02-20

8.  Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis.

Authors:  Mark D Singh; Vicky King; Helen Baldwin; David Burden; Anne Thorrat; Susan Holmes; Iain B McInnes; Ruairidh Nicoll; Kave Shams; Kenneth Pallas; Thomas Jamieson; Kit Ming Lee; Jose M Carballido; Antal Rot; Gerard J Graham
Journal:  Am J Pathol       Date:  2012-08-04       Impact factor: 4.307

9.  The Atypical Chemokine Receptor ACKR2 is Protective Against Sepsis.

Authors:  Fernanda V E Silva Castanheira; Vanessa Borges; Fabiane Sônego; Alexandre Kanashiro; Paula B Donate; Paulo H Melo; Kenneth Pallas; Remo C Russo; Flávio A Amaral; Mauro M Teixeira; Fernando S Ramalho; Thiago M Cunha; Foo Y Liew; José C Alves-Filho; Gerard J Graham; Fernando Q Cunha
Journal:  Shock       Date:  2018-06       Impact factor: 3.454

10.  Spread of Psoriasiform Inflammation to Remote Tissues Is Restricted by the Atypical Chemokine Receptor ACKR2.

Authors:  Kave Shams; Gillian J Wilson; Mark Singh; Ellen H van den Bogaard; Michelle L Le Brocq; Susan Holmes; Joost Schalkwijk; A David Burden; Clive S McKimmie; Gerard J Graham
Journal:  J Invest Dermatol       Date:  2016-08-26       Impact factor: 8.551

View more
  5 in total

Review 1.  The Role of Atypical Chemokine Receptor D6 (ACKR2) in Physiological and Pathological Conditions; Friend, Foe, or Both?

Authors:  Arezoo Gowhari Shabgah; Farhad Jadidi-Niaragh; Hamed Mohammadi; Farnoosh Ebrahimzadeh; Maziar Oveisee; Abbas Jahanara; Jamshid Gholizadeh Navashenaq
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

2.  The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B.

Authors:  Giulia D'Uonnolo; Nathan Reynders; Max Meyrath; Dayana Abboud; Tomasz Uchański; Toon Laeremans; Brian F Volkman; Bassam Janji; Julien Hanson; Martyna Szpakowska; Andy Chevigné
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

3.  Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients.

Authors:  Christophe M Capelle; Séverine Ciré; Olivia Domingues; Isabelle Ernens; Fanny Hedin; Aurélie Fischer; Chantal J Snoeck; Wim Ammerlaan; Maria Konstantinou; Kamil Grzyb; Alexander Skupin; Cara L Carty; Christiane Hilger; Georges Gilson; Aljosa Celebic; Paul Wilmes; Antonio Del Sol; Ian M Kaplan; Fay Betsou; Tamir Abdelrahman; Antonio Cosma; Michel Vaillant; Guy Fagherazzi; Markus Ollert; Feng Q Hefeng
Journal:  Cell Rep Med       Date:  2022-03-29

Review 4.  Potential Therapeutic Role of Mesenchymal-Derived Stem Cells as an Alternative Therapy to Combat COVID-19 through Cytokines Storm.

Authors:  Tarun Kumar Upadhyay; Rashmi Trivedi; Fahad Khan; Pratibha Pandey; Amit Baran Sharangi; Harsh Goel; Mohd Saeed; Moon Nyeo Park; Bonglee Kim
Journal:  Cells       Date:  2022-08-29       Impact factor: 7.666

5.  β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the same GPCR in living cells.

Authors:  Raphael S Haider; Edda S F Matthees; Julia Drube; Mona Reichel; Ulrike Zabel; Asuka Inoue; Andy Chevigné; Cornelius Krasel; Xavier Deupi; Carsten Hoffmann
Journal:  Nat Commun       Date:  2022-09-26       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.